Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness

Parkinsonism and Related Disorders

Volumn 3, Issue 1, 1997, Pages 1-6

  Hauser, Robert A ^a,d   Zesiewicz, Theresa A ^a   Factor, Stewart A ^b   Guttman, Mark ^e   Weiner, William J ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Parkinson's Dis Movement Disord C   (United States)

^e NONE

Author keywords

Clinical trials; Efficacy; Medications; Parkinson's disease; Protocols; Usefulness

Indexed keywords

CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

DRUG EFFICACY; DYSKINESIA; HALLUCINATION; HUMAN; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030623292     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(96)00042-9     Document Type: Note

References (21)

1. 1. Rinne U. K. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985; 35: 1196-1198.
2. 2. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5 year follow-up. Neurology 1987; 37: 826-828.
3. 3. Rinne U. K. Early dopamine agonist therapy in Parkinson's disease. Movement Disorders 1989; 4: 586-594.
4. 4. Olanow C. W. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Canadian Journal of Neurological Science 1992; 19: 108-112.
5. 5. Sivertsen B., Dupont E., Mikkelsen B., Mogensen P., Rasmusssen C., Boesen F., Heinonen E. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short-and long-term study. Acta Neurologica Scandinavica 1989; 126: 147-152.
6. 6. Factor S. A., Weiner W. J. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Movement Disorders 1993; 8 (3): 257-262.
7. 7. Weiner W. J., Factor S. A., Sanchez-Ramos J. R., Singer C., Sheldon C., Cornelius L., Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993; 43: 21-26.
8. 8. Brannan T., Yahr M. D. Comparative study of selegiline plus 1-dopa-carbidopa versus 1-dopa-carbidopa alone in the treatment of Parkinson's disease. Annals of Neurology 1995; 37: 95-98.
9. 9. Diamond S. G., Markham C. H., Treciokas L. J. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985; 35: 291-295.
10. 10. Jankovic J., Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Advances in Neurology 1986; 45: 551-554.
11. 11. Olanow C. W., Alberts M. J. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease. Advances in Neurology 1986; 45: 555-560.
12. 12. Ahlskog J. E., Muenter M. D. Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clinic Proceedings 1988; 63: 969-977.
13. 13. Olanow C. W., Fahn S., Muenter M., et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Movement Disorders 1994; 9: 40-47.
14. 14. Mackenzie R. A., Lance J. W. A double-blind trial of bromocriptine in Parkinson's disease. Medical Journal of Australia 1978; 2 (Suppl 3): 27-28.
15. 15. Jansen E. N. H. Bromocriptine in levodopa response-losing parkinsonism: a double blind study. European Neurology 1978; 17: 92-99.
16. 16. Schachter M., Marsden C. D., Parkes J. D., Jenner P., Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. Journal of Neurology Neurosurgery and Psychiatry 1980; 43: 1016-1021.
17. 17. Lang A. E., Quinn N., Brincat S., Marsden C. D., Parkes J. D. Pergolide in late-stage Parkinson disease. Annals of Neurology 1982; 12: 243-247.
18. 18. Lera G., Vaamonde J., Rodriguez M., Obeso J. A. Cabergoline in Parkinson's disease. Neurology 1993; 43: 2587-2590.
19. 19. Glantz R., Goetz C. G., Nausieda P. A., Weiner W. J., Klawans H. L. The effect of bromocriptine (BCT) on the on-off phenomenon. Journal of Neural Transmission 1981; 52: 41-47.
20. 20. Ogasahar S., Nishikawa Y., Takahashi M., Wada K., Nakamura Y., Yorifuji S., Tarui S. Dopamine metabolism in the central nervous system after discontinuation of 1-dopa therapy in patients with Parkinson disease. Journal of Neurological Science 1984; 66: 151-163.
21. 21. Hauser R. A., Olanow C. W. and Koller W. C. Time course of wash-out of symptomatic medication in Parkinson's disease. Neurology 1994, 44(suppl 2), 258.